Moderna, Inc. (MRNA)
Moderna's Revenue Warning Sends the Stock Into the Red for 2024
Moderna (MRNA) shares plunged after the COVID-19 vaccine maker slashed its outlook on lower demand in Europe and a tough market in the U.S.
Moderna Stock Gaps Lower After Earnings
Moderna Inc (NASDAQ:MRNA) stock is freefalling this morning, last seen down 15.2% to trade at $95.48 and pacing for its worst day since November 2021 after the company's second-quarter financial results.
Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates
Moderna (MRNA) came out with a quarterly loss of $3.33 per share versus the Zacks Consensus Estimate of a loss of $3.47. This compares to loss of $3.62 per share a year ago.
Moderna's stock slides 12% after it lowers full year sales guidance
Moderna Inc.'s stock MRNA tumbled 12% premarket Thursday, after the biotech cut its sales guidance for 2024, offsetting a narrower-than-expected second-quarter loss and revenue that topped estimates. Moderna had a net loss of $1.3 billion, or $3.33 a share, for the quarter, after a loss of $1.4 billion, or $3.62 a share, in the year-earlier period.
Moderna beats estimates but slashes guidance on low EU sales, competitive U.S. vaccine market
Moderna reported second-quarter revenue that beat estimates and a narrower than-expected loss for the period. But the company slashed its full-year sales guidance, citing lower sales in Europe, a "competitive environment" for respiratory vaccines in the U.S. and the potential for deferred international revenue into 2025.
Moderna reins in 2024 sales forecast, expects very low EU vaccine revenue
Moderna slashed its 2024 forecast for sales of its COVID-19 and respiratory syncytial virus vaccines by up to 25%, or $1 billion, on Thursday as it expects very low sales to the EU this year.
Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates
Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33) Updates 2024 financial framework and revises expectations for product sales to $3.0 to $3.5 billion Received U.S. FDA approval for RSV vaccine, mRESVIA, and began shipping in July; received EMA positive opinion in June Announced positive Phase 3 data for combination vaccine against influenza and COVID-19 Announced positive Phase 3 data for next-generation COVID-19 vaccine CAMBRIDGE, MA / ACCESSWIRE / August 1, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2024. "During the second quarter, we marked the approval of our second mRNA product and significantly lowered our operating costs.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
NEW YORK, NY / ACCESSWIRE / July 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ:MRNA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Moderna: State Of Play Ahead Of Q2 Earnings, I'm (Temporarily) Pessimistic
Moderna will announce Q2 2024 earnings this Thursday, 1st August. Moderna stock hit highs of $450 per share in late 2021, but has since seen a decrease ~$120, and a current market cap valuation of ~$47bn. Revenue guidance for 2024 is for $4bn, although this is primarily dependent on the emergence of a significant private COVID-19 vaccination market, which is not guaranteed.
Exploring Analyst Estimates for Moderna (MRNA) Q2 Earnings, Beyond Revenue and EPS
Beyond analysts' top -and-bottom-line estimates for Moderna (MRNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?
Investors will likely focus on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.
Why Moderna (MRNA) Dipped More Than Broader Market Today
The latest trading day saw Moderna (MRNA) settling at $121.25, representing a -1.02% change from its previous close.
